SCHEMBL15567237 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	PSMD14	O00487	1/20	0.44

▸	MAPK1	P28482	4/20	0.41

▸	ATM	Q13315	1/20	0.41

▸	KDM4E	B2RXH2	4/20	0.39

▸	L3MBTL1	Q9Y468	1/20	0.39

▸	MAP2K4	P45985	2/20	0.39

▸	KDM6B	O15054	1/20	0.37

▸	KDM5C	P41229	1/20	0.37

▸	KDM4C	Q9H3R0	1/20	0.37

▸	KDM2A	Q9Y2K7	1/20	0.37

▸	KDM3A	Q9Y4C1	1/20	0.37

▸	STAT3	P40763	1/20	0.37

▸	HIF1A	Q16665	1/20	0.37

▸	DYRK1A	Q13627	2/20	0.36

▸	HPGDS	O60760	1/20	0.36

▸	ALDH1A1	P00352	1/20	0.36

▸	POLB	P06746	1/20	0.36

▸	MAPT	P10636	1/20	0.36

▸	KIF11	P52732	1/20	0.35

▸	FLT3	P36888	1/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17981585	0.85	CYP2C19 (0.44)	KDM4EL3MBTL1ALDH1A1MAPTCA12
SCHEMBL16968677	0.82	PSMD14 (0.44)	PSMD14MAPK1ATMKDM4EL3MBTL1
SCHEMBL15570495	0.81	HCAR2 (0.41)	PSMD14MAPK1KDM4EMAP2K4KDM5C
SCHEMBL30908123	0.78	MAPK1 (0.41)	PSMD14MAPK1ATMKDM4EL3MBTL1
SCHEMBL13387047	0.78	MAPK1 (0.41)	PSMD14MAPK1ATMKDM4EL3MBTL1
SCHEMBL13386939	0.77	PSMD14 (0.44)	PSMD14MAPK1ATMKDM4EL3MBTL1
SCHEMBL348514	0.75	MAP2K4 (0.54)	KDM4EL3MBTL1MAP2K4STAT3HIF1A
SCHEMBL1505593	0.73	MAPK1 (0.53)	PSMD14MAPK1ATMKDM4EL3MBTL1
SCHEMBL15417877	0.72	KDM4E (0.38)	MAPK1ATMKDM4EL3MBTL1MAP2K4
SCHEMBL13132281	0.72	MAP2K4 (0.43)	MAPK1KDM4EL3MBTL1MAP2K4STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2025053379-A1	NOVEL COMPOUND AND USE THEREOF FOR TREATING PSORIASIS	광주과학기술원	2025-03-13	—	—	WO	disclosed
US-10196354-B2	4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof	MERCK SHARP & DOHME CORP. (US)	2019-02-05	—	—	US	disclosed
EP-2884981-B1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME (US)	2018-06-20	—	—	EP	disclosed
EP-2884981-B1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME (US)	2018-06-20	—	—	EP	disclosed
US-20180022701-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME LLC	2018-01-25	—	—	US	disclosed
US-20180022701-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME LLC	2018-01-25	—	—	US	disclosed
US-9745265-B2	4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof	MERCK SHARP & DOHME CORP. (US)	2017-08-29	—	—	US	disclosed
US-9745265-B2	4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof	MERCK SHARP & DOHME CORP. (US)	2017-08-29	—	—	US	disclosed
US-9745265-B2	4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof	MERCK SHARP & DOHME CORP. (US)	2017-08-29	—	—	US	disclosed
US-20150218096-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME LLC	2015-08-06	—	—	US	disclosed
US-20150218096-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME LLC	2015-08-06	—	—	US	disclosed
US-20150218096-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME LLC	2015-08-06	—	—	US	disclosed
EP-2884981-A2	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	Merck Sharp & Dohme Corp. (US)	2015-06-24	—	—	EP	disclosed
WO-2014028589-A2	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME CORP. (US)	2014-02-20	—	—	WO	disclosed
WO-2014026327-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF	MERCK SHARP & DOHME CORP. (US)	2014-02-20	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-10196354-B2	4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof	RORB, RORA, RORC	PSMD14 3754/4885MAPK1 2124/4885ATM 4848/4885
US-20180022701-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	RORB, RORA, RORC	PSMD14 3754/4885MAPK1 2124/4885ATM 4848/4885
US-20150218096-A1	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF	RORB, RORA, RORC	PSMD14 3754/4885MAPK1 2124/4885ATM 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.